Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Copeland

Showing results (441-450 of 450) with videos related to

Pageof 45
Sort By:
You have reached the last page of results.This site can display upto 450 results.
MMWR. Morbidity and Mortality Weekly Report|September 22, 2022
Two Cases of Monkeypox-Associated Encephalomyelitis - Colorado and the District of Columbia, July-August 2022Daniel M Pastula, Matthew J Copeland, Markus C Hannan, et al.
Transplantation|February 24, 2001
Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine--results at 24 months after transplantationH J Eisen, R E Hobbs, S F Davis, et al.
Nucleic Acids Research|December 19, 2003
E-MSD: an integrated data resource for bioinformaticsA Golovin, T J Oldfield, J G Tate, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2025
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized studyIgnace Vergote, Larry J Copeland, Toon Van Gorp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian CancerKrishnansu S Tewari, Robert A Burger, Danielle Enserro, et al.
British Journal of Anaesthesia|March 24, 2024
International consensus is needed on a core outcome set to advance the evidence of best practice in cancer prehabilitation services and researchAnna M Myers, Rachael C Barlow, Gabriele Baldini, et al.
Future Oncology (London, England)|July 11, 2024
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer"Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2025
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)Brian M Slomovitz, S John Weroha, Wei Deng, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 23, 2014
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriersPaolo Peterlongo, Jenny Chang-Claude, Kirsten B Moysich, et al.
Pageof 45

Showing results (441-450 of 450) with videos related to

Sort By:
Pageof 45
You have reached the last page of results.This site can display upto 450 results.
MMWR. Morbidity and Mortality Weekly Report|September 22, 2022
Two Cases of Monkeypox-Associated Encephalomyelitis - Colorado and the District of Columbia, July-August 2022Daniel M Pastula, Matthew J Copeland, Markus C Hannan, et al.
Transplantation|February 24, 2001
Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine--results at 24 months after transplantationH J Eisen, R E Hobbs, S F Davis, et al.
Nucleic Acids Research|December 19, 2003
E-MSD: an integrated data resource for bioinformaticsA Golovin, T J Oldfield, J G Tate, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2025
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized studyIgnace Vergote, Larry J Copeland, Toon Van Gorp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian CancerKrishnansu S Tewari, Robert A Burger, Danielle Enserro, et al.
British Journal of Anaesthesia|March 24, 2024
International consensus is needed on a core outcome set to advance the evidence of best practice in cancer prehabilitation services and researchAnna M Myers, Rachael C Barlow, Gabriele Baldini, et al.
Future Oncology (London, England)|July 11, 2024
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer"Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2025
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)Brian M Slomovitz, S John Weroha, Wei Deng, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 23, 2014
Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriersPaolo Peterlongo, Jenny Chang-Claude, Kirsten B Moysich, et al.
Pageof 45